Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories, with a price target of $109.00. The company’s shares closed yesterday at $90.50.

Introducing TipRanks MCP for Agents

• Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
• Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Boston Scientific, and Dexcom. According to TipRanks, Biegelsen has an average return of 1.2% and a 48.30% success rate on recommended stocks.

Currently, the analyst consensus on Abbott Laboratories is a Strong Buy with an average price target of $119.76, which is a 32.33% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $120.00 price target.

Based on Abbott Laboratories’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $11.16 billion and a net profit of $1.08 billion. In comparison, last year the company earned a revenue of $10.36 billion and had a net profit of $1.33 billion

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABT in relation to earlier this year. Most recently, in April 2026, Daniel Starks, a Director at ABT bought 10,000.00 shares for a total of $926,500.00.